Surge In Cancer Diagnoses Drives Breakthroughs In Precision Treatment Technologies Driver: A Major Catalyst in the Evolution of the Oncolytic Adenovirus Market in 2025

What industry-specific factors are fueling the growth of the oncolytic adenovirus market?
The growing incidence of cancer is expected to drive the growth of the oncolytic adenovirus market. Cancer, characterized by uncontrolled cell growth and spread to other parts of the body, is increasing due to aging populations, environmental exposures, lifestyle factors, genetic predispositions, and improved detection methods. Oncolytic adenoviruses target and selectively kill cancer cells, offering a promising treatment for the rising incidence of cancer. For instance, in May 2024, the National Cancer Institute (NCI) reported nearly 20 million new cancer cases and 9.7 million deaths worldwide, with projections for 2040 rising to 29.9 million cases and 15.3 million deaths. Additionally, in 2023, the Australian Bureau of Statistics, an Australian government agency, reported that 1.8% of Australians had cancer, with males (2.1%) slightly more affected than females (1.6%), particularly those aged 75 and older. Therefore, the increasing incidence of cancer is driving the growth of the oncolytic adenovirus market.

Get Your Oncolytic Adenovirus Market Report Here:
https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

What Is the projected market size and growth rate for the oncolytic adenovirus market?
The oncolytic adenovirus market has seen strong expansion, growing from $122.31 billion in 2024 to $132.87 billion in 2025 at a CAGR of 8.6%. Growth has been driven by an increasing cancer burden, a rising demand for targeted therapies, growing R&D funding, improved delivery technologies, and regulatory approvals.

The oncolytic adenovirus market is projected to witness significant growth, reaching $183.22 billion by 2029, at a CAGR of 8.4%. Growth will be fueled by an increasing cancer burden, expansion of combination therapies, regulatory advancements, technological improvements in viral engineering, and increased investment in oncology research. Key trends include enhancements in viral engineering techniques, next-generation drug delivery systems, improved tumor targeting methods, advancements in immunotherapy combinations, and innovations in patient monitoring and diagnostics.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

What new trends are reshaping the oncolytic adenovirus market and its opportunities?
In the oncolytic adenovirus market, companies are focusing on combination therapies such as VCN-01, which combines oncolytic virotherapy with chemotherapy to enhance tumor targeting and therapeutic outcomes. For instance, in May 2024, Theriva Biologics, a US-based immuno-oncology company, announced that the FDA granted Fast Track Designation for its lead candidate VCN-01. When used in combination with gemcitabine and nab-paclitaxel, VCN-01 targets and infects tumor cells, enhancing chemotherapy's effectiveness by breaking down the tumor stroma-one of the key barriers to cancer treatment. This combination approach aims to improve the treatment of metastatic pancreatic adenocarcinoma and potentially other solid tumors.

What major market segments define the scope and growth of the oncolytic adenovirus market?
The oncolytic adenovirus market covered in this report is segmented -

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types
2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications
3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes

Subsegments:
1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based, Second-generation Adenovirus Type 5-based, Engineered Adenovirus Type 5-based
2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based, Second-generation Adenovirus Type 2-based, Engineered Adenovirus Type 2-based
3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21235

Which region dominates the oncolytic adenovirus market?
North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which key market leaders are driving the oncolytic adenovirus industry growth?
Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

What Is Covered In The Oncolytic Adenovirus Global Market Report?

•Market Size Forecast: Examine the oncolytic adenovirus market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the oncolytic adenovirus market for a structured understanding.
•Key Players Overview: Analyze major players in the oncolytic adenovirus market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the oncolytic adenovirus market.
•Segment Contributions: Evaluate how different segments drive overall growth in the oncolytic adenovirus market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the oncolytic adenovirus market.
•Industry Challenges: Identify potential risks and obstacles affecting the oncolytic adenovirus market.
•Competitive Landscape: Review strategic developments in the oncolytic adenovirus market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.